Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lung-Yi Mak, Wai-Kay Seto, James Fung & Man-Fung Yuen. (2019) Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 12:2, pages 109-120.
Read now
Read now
Martti Färkkilä. (2010) This month in Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 45:1, pages 3-5.
Read now
Read now
Articles from other publishers (31)
Yi‐Cheng Chen, Chao‐Wei Hsu & Rong‐Nan Chien. (2023) Higher HBeAg‐reversion virological relapse and lower sustained remission after treatment cessation in tenofovir‐treated HBeAg‐positive patients. Journal of Medical Virology 95:11.
Crossref
Crossref
Florian van Bömmel & Thomas Berg. (2021) Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B. Hepatology Communications 5:10, pages 1632-1648.
Crossref
Crossref
Apichat Kaewdech & Pimsiri Sripongpun. (2021) Challenges in the discontinuation of chronic hepatitis B antiviral agents. World Journal of Hepatology 13:9, pages 1042-1057.
Crossref
Crossref
Wen-Juei Jeng & Yun-Fan Liaw. (2021) Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Seminars in Liver Disease 41:03, pages 349-357.
Crossref
Crossref
Jia-Horng Kao, Wen-Juei Jeng, Qin Ning, Tung-Hung Su, Tai-Chung Tseng, Yoshiyuki Ueno & Man-Fung Yuen. (2021) APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatology International 15:4, pages 833-851.
Crossref
Crossref
Tao Li, Yan Liang, Meng Zhang, Feng Liu, Lixin Zhang, Baohua Yang & Lei Wang. (2021) Nucleoside/nucleotide analog consolidation therapy in hepatitis B e‐antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatology Research 51:6, pages 633-640.
Crossref
Crossref
Yan Xue, Meng Zhang, Tao Li, Feng Liu, Li-Xin Zhang, Xiao-Ping Fan, Bao-Hua Yang & Lei Wang. (2021) Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World Journal of Gastroenterology 27:14, pages 1497-1506.
Crossref
Crossref
Shi‐Chi Wen, Chi‐Chang Tsai, Lung‐Chih Cheng, Chien‐Wei Huang & Wu‐Hsien Kuo. (2020) Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding. Advances in Digestive Medicine 8:1, pages 10-18.
Crossref
Crossref
Issam Tout, Pietro Lampertico, Thomas Berg & Tarik Asselah. (2021) Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Research 185, pages 104992.
Crossref
Crossref
K. Seng Liem, Adam J. Gehring, Jordan J. Feld & Harry L.A. Janssen. (2020) Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 158:5, pages 1185-1190.
Crossref
Crossref
Florian Bömmel & Thomas Berg. 2020. Clinical Dilemmas in Viral Liver Disease. Clinical Dilemmas in Viral Liver Disease
175
181
.
Margarita Papatheodoridi & George Papatheodoridis. (2019)
Can we stop nucleoside analogues before
HB
sAg loss?
. Journal of Viral Hepatitis.
Crossref
Crossref
Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel & Juan Ramón Larrubia. (2018) Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?. World Journal of Gastroenterology 24:17, pages 1825-1838.
Crossref
Crossref
M. J. Tong, C. Q. Pan, S.-H. B. Han, D. S.-K. Lu, S. Raman, K.-Q. Hu, J. K. Lim, H. W. Hann & A. D. Min. (2018) An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 47:8, pages 1181-1200.
Crossref
Crossref
S. Van Hees, S. Bourgeois, H. Van Vlierberghe, T. Sersté, S. Francque, P. Michielsen, D. Sprengers, H. Reynaert, J. Henrion, S. Negrin Dastis, J. Delwaide, L. Lasser, J. Decaestecker, H. Orlent, F. Janssens, G. Robaeys, I. Colle, P. Stärkel, C. Moreno, F. Nevens & T. Vanwolleghem. (2018) Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Alimentary Pharmacology & Therapeutics 47:8, pages 1170-1180.
Crossref
Crossref
Florian van Bömmel & Thomas Berg. (2018) Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver International 38, pages 90-96.
Crossref
Crossref
Sebastián Marciano & Adrián Gadano. (2018) Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver International 38, pages 97-101.
Crossref
Crossref
Seong Hee Kang, Keunhee Kang, Yeon Jong Eun, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Eileen L. Yoon, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim & Kwan Soo Byun. (2017) Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. Journal of Medical Virology 89:5, pages 849-856.
Crossref
Crossref
Chern Hao Chong & Seng Gee Lim. (2017) When can we stop nucleoside analogues in patients with chronic hepatitis B?. Liver International 37, pages 52-58.
Crossref
Crossref
George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi & Jörg Petersen. (2016) Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 63:5, pages 1481-1492.
Crossref
Crossref
Chien-Hung Chen, Chao-Hung Hung, Tsung-Hui Hu, Jing-Houng Wang, Sheng-Nan Lu, Pei-Fang Su & Chuan-Mo Lee. (2015) Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology 13:11, pages 1984-1992.e1.
Crossref
Crossref
Tse-Ling Fong, Andy Tien, Kahee J. Jo, Danny Chu, Eddie Cheung, Edward A. Mena, Quang-Quoc Phan, Andy S. Yu, Wafa Mohammed, Andrew Velasco, Vinh-Huy LeDuc, Nickolas Nguyen, Steven-Bui Han, Mimi Chang, Ho S. Bae, Yong-Won Cho, Myron J. Tong & Stewart L. Cooper. (2015) Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Digestive Diseases and Sciences 60:11, pages 3465-3472.
Crossref
Crossref
Chih-Chien Yao, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Mei-Chin Hsu & Chien-Hung Chen. (2015) Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. Journal of Gastroenterology and Hepatology 30:5, pages 918-924.
Crossref
Crossref
Hyung Rae Sohn, Bo Young Min, Joon Chang Song, Mun Hyuk Seong, Sang Soo Lee, Eun Sun Jang, Cheol Min Shin, Young Soo Park, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee & Jin-Wook Kim. (2014) Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infectious Diseases 14:1.
Crossref
Crossref
Li-Fu Kuo, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien & Chien-Hung Chen. (2014) High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Digestive Diseases and Sciences 59:10, pages 2580-2587.
Crossref
Crossref
E. Ridruejo, S. Marciano, O. Galdame, M. V. Reggiardo, A. E. Muñoz, R. Adrover, D. Cocozzella, N. Fernandez, C. Estepo, M. Mendizábal, G. A. Romero, D. Levi, T. Schroder, S. Paz, H. Fainboim, O. G. Mandó, A. C. Gadano & M. O. Silva. (2014) Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. Journal of Viral Hepatitis 21:8, pages 590-596.
Crossref
Crossref
Cheng-Yuan Peng. (2013) Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. Current Hepatitis Reports 12:3, pages 181-187.
Crossref
Crossref
Kevin T. Chaung, Nghiem B. Ha, Huy N. Trinh, Ruel T. Garcia, Huy A. Nguyen, Khanh K. Nguyen, Gabriel Garcia, Aijaz Ahmed, Emmet B. Keeffe & Mindie H. Nguyen. (2012) High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy. Journal of Clinical Gastroenterology 46:10, pages 865-870.
Crossref
Crossref
Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, Ed Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin-Lin Hou, Wan-Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong-Jin Suh & Masao Omata. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 6:3, pages 531-561.
Crossref
Crossref
Myron J. Tong, Calvin Q. Pan, Hie-Won Hann, Kris V. Kowdley, Steven-Huy B. Han, Albert D. Min & Truong-Sinh Leduc. (2011) The Management of Chronic Hepatitis B in Asian Americans. Digestive Diseases and Sciences 56:11, pages 3143-3162.
Crossref
Crossref
Kyung Hee Kim, Dong Hyun Sinn, Won Kyoung Yun, Hyun Chin Cho, Yun Young Lee, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo & Seung Woon Paik. (2011) Defining Virologic Relapse in Chronic Hepatitis B. Digestive Diseases and Sciences 56:8, pages 2432-2438.
Crossref
Crossref